share_log

Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Benzinga ·  Dec 4 20:21

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $10 to $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment